BioNTech (NasdaqGS:BNTX) last closed at US$96.96, leaving investors weighing how current pricing aligns with recent trading ...

BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.

BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall ...

Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and ...

New data, updated guidance, and shifting sentiment are quietly changing how people think about the BioNTech COVID vaccine. Here’s what’s actually new, what isn’t, and how it affects you in the US ...

BioNTech SE's $11.1bn BMS deal for BNT-327 highlights promise in PD-L1/VEGF oncology, but clinical validation is still needed. Despite strong COVID vaccine cash flow, BioNTech's share price stagnates ...

Pfizer and its German partner BioNTech are ending a clinical trial they agreed to run in 2025 when receiving approval from U.S. authorities for their updated COVID-19 immunization. A BioNTech ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies are on different paths. Both Moderna and BioNTech helped pioneer mRNA, or messenger RNA, ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An illustration photo shows a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine from Skippack ...

Law360 (June 23, 2026, 5:25 PM EDT) -- A former senior clinical trial manager at BioNTech US Inc. told a North Carolina federal court Monday that she was wrongfully fired after complaining to ...

German pharmaceutical giant BioNTech, known worldwide for its development of a coronavirus vaccine, is set to close three ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...